Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Geron Stock Soared 23.4% Today

TheMotleyFool

0 0

After four abstracts were released highlighting the latest data on its lead drug candidate, imetelstat, shares of Geron (NASDAQ: GERN) were trading 23.4% higher as of 1:21 p.m. EST on Friday.

Previously, Geron's prospects were dealt a significant blow when former imetelstat co-developer Johnson & Johnson decided against advancing the drug into phase 3 studies following lackluster mid-stage trial results in myelodysplastic syndromes (MDS) and myelofibrosis. After Geron received the rights to imetelstat back from J&J, it initiated a phase 3 study in MDS and paused development in MF.

IMAGE SOURCE: GETTY IMAGES.

Source Fool.com

Like: 0

GERN

Share